Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Biomark Diagnostics Inc. (C:BUX)

Business Focus: Bio Diagnostics & Testing

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for BUX within the last 6 months
See all filings within the past 6 months

Company News

Dec 04, 2023 08:30 ET
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023. This patent entitled "Detection and Quantification of Acetylamantadine in Urine Sample" belongs to our legacy assay and its claims cover BioMark's response to treatment assay.
Read full article
Nov 28, 2023 08:30 ET
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results from the second quarter ended September 30, 2023. The Company also announces that it intends to extend the warrant exercise term in a continuing effort to improve corporate value for its shareholders.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 15, 2023814338
Oct 31, 2023476112
Oct 15, 2023364199
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. It has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

See business summary



Search (past week) for $BUX.CA

  • No tweets found